Effects of medication in the rehabilitation of persons with substance-induced disorders:
EFFECTS OF MEDICATION IN THE REHABILITATION OF PERSONS WITH
CASE STUDIES AT SPECIALIST HOSPITAL BAUCHI
DURING THE 8TH BIENNIAL CONFERENCE ON “ALCOHOL, DRUGS AND
SOCIETY IN AFRICA” ORGANISED BY CENTER FOR RESEARCH AND
INFORMATION ON SUBSTANCE ABUSE (CRISA) AT CHELSEA HOTEL,
Department of Psychiatry, Specialist Hospital Bauchi.
Effects of Medication in the Rehabilitation of Persons with Substance-Induced Disorders Background:
Substance-related disorders simply refers to disorders
related to the taking of a substance of abuse, the side effects of
a medication, or the exposure to a toxin. One of these will be
referred to as substance abuse which literally means substance
abnormal use. The essential feature of abuse is a maladaptive
pattern of substance use manifested by recurrent and
significant adverse consequences related to the repeated use of
substances. There may be repeated failure to fulfill major role
obligations, repeated use in situations in which it is physically
hazardous, multiple legal problems and a recurrent social and
interpersonal problems. The substances of abuse include
alcohol, amphetamines, caffeine, cannabis, cocaine,
hallucinogens, inhalants, nicotine, opioids, phencyclidine (PCP)
and sedatives, hypnotics, anxiolytics as well as other
Substance-induced disorders are marked psychiatric
symptoms experienced and or manifested due to the evils of
substance abuse. These include substance intoxication,
substance withdrawal, and disorders that could be classified in
the existing classes of psychoses. The essential feature of a
substance intoxication is the development of a reversible
substance-specific syndrome due to the recent ingestion of (or
exposure to) a substance. The clinically significant
maladaptive behavioural (or psychological) changes associated
with intoxication are due to the direct physiological effects of
the substance on the central nervous system and develop
during or shortly after use of the substance. The essential
feature of substance withdrawal is the development of a
substance-specific maladaptive behavioural change, with
physiological and cognitive concomitants, that is due to the
ceasation (or reduction in) heavy and prolonged substance use.
The substance-specific syndrome causes clinically significant
distress or impairement in social, occupational and other
important areas of functioning. Substance-induced disorders
cause a variety of symptoms that are characteristics of other
The persons with Substance-induced disorders are people
who experience and or manifest psychiatric symptoms due to
substance abuse, intoxication, withdrawl and the likes. Hence,
analysis of the logic underlying their biological intervention is a
valuable aid to improving biobehavioral research and practice
(Schwartz et al, 1978). This position concurs with and is in
pleasant support of the premise upon which the discourse
before us is hinged. Such a concise literature may only be
adjudged precise when a brief mention is made on treatment
Treatment Modalities:
The evidence-based treatment modalities for substance-
induced disorders could be categorized into psychosocial
approach and medical approach as the case may be. The
therapeutic interventions in psychosocial approach include:
While the interventions of medical approach include:
Alcohol Deterrent Therapy:
Alcohol deterrent therapy uses disulfiram (antabuse) to
deter those with disorders due to alcoholism to cease drinking.
The presence of disulfiram in the body makes one to hate
alcohol because of the unwanted interaction effects. The drug
inhibits enzyme aldehyde dehydrogenase thereby blocking the
oxidation of alcohol at the stage when acetaldehyde is converted
to acetate. This results in an accumulation of acetaldehyde in
the blood which is thought to produce disulfiram-alcohol
reaction. The reaction varies according to the sensitivity of the
individual and how much alcohol was ingested. Symptoms of
disulfiram-alcohol reaction can occur within 5-10 minutes of
alcohol ingestion. Such syndrome of symptoms can produce a
good deal of discomfort and can even result to death if the blood
Pharmacotherapies:
substance-induced disorders are two-fold, thus substitution
therapy, and replacement therapy which are better appreciated
Benzodiazepines are the most widely used group of drugs
for substitution therapy in alcohol withdrawal.
Chlordiazepoxide (Librium), oxazepam (serax), and Diazepam
(Velium) are most commonly used agents. The approach is to
start with relatively high doses and reduce the dosage by 20-25
percent each day until withdrawal is complete. In persons with
co-occuring liver disease, the shorter-acting benzodiazepine
(oxazepam) is more appropriate because the longer-acting are
problematic in this case. Certain anticonvulsant (Phenytoin,
Phenobarbital, or magnesium sulfate) medicaction could
manage withdrawal seizures, if intravenous diazepam or
lorazepam (ativan) failed (Bennett and Woolf, 1991).
Multivitamin and thiamine medication is common protocol in
replacement therapy. Thiamine which is required to prevent
nuoropathy, confusion and encephalopathy will be
unceremoniously deficient in chronic alcoholics.
Opiods include substances such as heroin, morphine,
opium, meperidine, codeine and methadone. Withdrawal
symptoms begin within 8-12 hours after the last opiod dose and
become most intense by 36-48 hours (Benneth & Woolf, 1991).
The acute phase of withdrawal is over approximately 10 days
while irritability and restlessness may persist for 2-3 months.
Opioid intoxication is treated with narcotic antagonists such as
naloxone (narcan), nalorphine (nalline), or levallorphan
(lorphan). Withdrawal therapy includes rest, adequate
nutritional support and methadone substitution. Clanidine
(catapres) is non-addicting and can serve as a bridge to enable
staying opiate-free long enough to initiate naltrexone (trexane)
therapy, which is use to facilitate termination of methadone
Substitution therapy for CNS depressants withdrawal
(particularly barbiturates) is commonly the long-acting
barbiturate Phenobarbital (Luminal). The required dosage is
given and will gradually be decreased by 30mg/day, when
stabilization is achieved, until withdrawal is complete. Long
acting benzodiazepines are commonly used for substitution
therapy when the abused substance is a non-barbiturate CNS
Treatment of stimulant intoxication usually begins with
minor tranquilifers (chlordiazepoxide) and progresses to major
tranguilizers (Haloperidol). Severe hypertension could be
treated with intravenous phentolamine (regitine) while
repeated seizures are treated with intravenous diazepam.
Treatment of withdrawal from stimulants is aimed at reducing
drug craving and managing severe depression. While a
conducive environment is created, free of anxiety and suicide,
the tricyclic antidepressants such as desipramine (norpramine)
could treat the symptoms of cocaine. Hallucinogens and
cannabinols are treated with benzodiazepines (Diazepam or
chlordiazepoxide) to prevent harm to self or others by the
patient. In case of psychotic reactions, phenothiazine or
haloperidol will be most appropriate (Townsend 1999, Bennett
Purpose of the Study:
Substance abuse and substance – induced disorders pose a
great deal of challenge to stakeholders and the society at large.
Hence, Lambo (1996) believed that “ we are still far from
achieving successes in conquering socially-induced and
psychologically-based disease which have greater and more
disastrous impact on the fabric of our contemporary society as
well as on individuals”. Considering the background of this
study and the brief literature reviewed herein, it is not out of
place to explore much more about the existing accessible
medication for substance-induced disorders. Moreso that most
of the medicinal substances reviewed in the preceding literature
might not be readily available or accessible to meet the need of
certain legitimate consumers. Hence, this study was designed to
investigate the effect of carbamazepine and antipsychotics plus
multivitamins medication in the rehabilitation of persons with
Study Setting & Population:
The study site, Specialist Hospital Bauchi, is a tertiary
health institution with 850 bed-capacity. Psychiatric
department of the hospital is one of the treatment centers for
substance-induced disorders. During the period of this study, 10
percent of the total service-users on the facility were psychiatric
inpatients. About 48 percent (representing 206) of the
psychiatric inpatients were persons with substance induced
Participants:
The 206 persons hospitalized during the period of study
formed the study participants. 95 percent of them aged 16-30
while five percent were within 30-41 years of age. Only, one
percent of the total participants were female while 99 percent
The substances so far abused with the corresponding rate
of participants include Alcohol (N=2), Amphetamine (N=2),
Cannabis (N=21), other stimulants (N=97), other depressants
(N=80) and inhalants (N=4) as from January 2007-2008 June.
Instruments/Apparatus:
Identification and secondary analysis of existing data
were the basis of initial assessment. A modified Core Data for
Drug Treatment reporting System, which is an indicator data
collection form, was the instrument used in obtaining
appropriate data for this clinical study.
Design and Procedure:
The 18-month clinical case studies have been designed to
explore how the independent variable (medication) affect the
dependent variable (substance-induced disorders).
The procedure starts, during admission process, by
systematic history taking and mental status examination. As
soon as any form of substance –induced disorder have been
diagnosed, the clinical case study of the individual patient
Medications such as carbamazepine, haloperidol,
chlorpromazine and multivitamins were prescribed and
administered according to the individual patient’s need. Such
need were defined in terms of the nature of substances abused,
severity of the disorder, medical status, age and personality of
Careful observation and continuous evaluation during and
after the administration of such medication formed the
procedural framework of the study. The oral medication
(a) Carbamazepine 200mg – 600mg daily in divided dose.
(b) Haloperidol 5mg – 80mg daily in divided dose.
(c) Chlorpromazine 100mg – 1000mg daily in divided dose.
These medicinal substances were periodically complemented
with certain multivitamins as the need arises. Neurobion and
related agents have been used in this case.
Oral Benzhexol 5mg accompanied each single or combined
doses of the above mentioned drugs. Benzhexol is very
necessary with antipsychotic medication whereas the
multivitamins depended on the need of individual persons.
Parenteral medications were more beneficial as the starting
dose of medication for chronic as well as extremely severe cases.
It also aided maintenance medication in case of questionable
Having had such medications as an inpatient, the individual
patients who recovered reasonably were discharged on
maintenance dose, to be taken at home. The least stay as an
inpatient was two weeks while the longest stay was two months
Identification and secondary analysis of existing data were
used in eliciting information that could not be obtained first-
hand. A modified version of the ‘Core Data for Drug Treatment
Reporting System” enabled the study to reveal the effectiveness
of such medication in substance-induced disorders. As an
indicator data collection form, it gave an insight on treatment
contact details, socio-demographic information, types and
consequences of the substances abused, medication compliance
After the 18 month study period, it was established that 70
percent of the inpatients fully recovered and were discharged
without any repalse. 20 percent experienced remissions and
relapses while the remaining 10 percent were non-compliant to
medication or treatments. Out of the non-compliant patients,
2% were referred to the rehabilitation unit of National Drug
Law Enforcement Agency. The remaining 8% were
unfortunately without any remedy, they remained as nuisance
Discussions
Medication still remains crucial in the treatment of
substances-induced disorders. The result of this study lend
credence to the effects of carbamazeine and antipsychotic
medication by facilitating recovery from the disorders. A case in
view was the lady (aged 24) diagnosed with severe substance-
induced disorder. She got into abusing the substances to enable
coping up and to compensate for her glaring deficiencies in
both social and academic life. Her symptoms were characterized
by agitation, aimless wandering, exhibitionism, hallucination
and restlessness. While taking carbamazepine, chlorpromazine,
haloperidol, benzhexol and multivitamins as in-patient, she
recovered fully and was discharged after just two weeks
hospitalization. The lady continued on maintenance dose for 10
months at home and have been living medication free for the
past seven months now without any relapse. Such finding have
been in harmony with clinical trials and other evidence-based
studies earlier conducted by experts in drug field.
Carbamazepine Indications:
According to controlled clinical trials, carbamazepine has
been shown to be effective in the treatment of psychomotor and
grandmal seizures as well as in trigeminal neuralgia. It
relieves the pain associated with trigeminal neuralgia often
within 24-48 hours. Beneficial results have also been reported
in glossopharyngeal neuralgia. Carbamazepine have been
discovered highly effective in mania, bipolar disorders and
epilepsy. The evidence supporting the efficacy of carbamazepine
as an anticonvulsant was derived from active drug controlled
studies that enrolled patients with the following types:
• Partial seizures with complex symptomatology (psychotor
and temporal lobe). Patients with these seizures appear to
show greater improvement than those with other types.
• Generalised tonic-clonic seizures (grandmal). • Mixed seizure patterns with one or both of the above.
The Antipsychotics:
The term “antipsychotic” describes a group of drugs used
mainly for treating psychotic disorders (such as schizophiemia,
mania and others) or agitated states. Such drugs are also
referred to as neuroleptics which connotes their capacity to
affect several integrating systems of the brain. Antipsychotic
drugs produce a specific improvement in the mood and
behaviour of psychotic patients, without excessive sedation and
without causing addiction. They interfere with normal amine
transmission in the brain and may produce extrapyramidal
symptoms and signs. The four classes of antipsychotic drugs
are phenothiazine derivatives, thioxanthene derivatives,
butyrophenone derivatives and miscellaneous structure. Of
particular interest in this discussion are chlorpromazine and
Chlorpromazine Indication:
Chlorpromazine is a neuroleptic in aliphatic family of
phenothiazine derivatives. It is well absorbed when given
orally, but there is a significant “first-pass metabolism” which
results in very low plasma concentrations of the under-changed
drug. The duration of drug action is of the order of 6-8 hours.
Chlorpromazine have been found to be exerting both calming
and somewhat sedating effect. It has significant effect in
schizophrenia and related psychoses as well as in nausea and
vomiting of terminal illness. Chlorpromazine have secondary
effect of improving appetite and other negligible advantages to
Haloperidol Indication:
Haloperidol is a butyropherone derivative with
antipsychotic properties that has been considered particularly
effective in the management of hyperactivity, agitation and
mania. It is an effective neuroleptic and also possesses
antiemetic properties. It has a marked tendency to provoke
extrapyramidal effects and have relatively weak alpha-
adrenolytic properties. It may also exhibit hypothermic and
anorexiant effects and potentiate the action of barbiturates,
general anaesthetics, and other CNS depressant drugs. The
peak plasma level of Haloperidol occur within 2-8 hours of oral
dosing and then after just 20 minutes of intramuscular
injection. The long-acting parenteral Haloperidol are
antipsychotics intended for use in the management of patients
requiring prolonged therapy as in the case of chronic
Haloperidol is a more potent dopamine antagonist as well
as less potent receptor antagonist and have only weak atropine-
like activity. It acts by blocking the post-synaptic dopamine
receptors in the brain. The indications also include dementia,
oligophrenia, psychopathy, alcoholism, delusion, hallucinations,
Multivitamins:
The multivitamins are significant for nourishing the
brain. Neurotrasmitters and other structures in the brain
system need nourishment to facilitate recovery and maintain
optimal functioning. Drugs such as Neurobion, vitamin B
Complex and other related ones are of great importance in this
Benzhexol Indication:
Benzhexol is an antidote to antipsychotic drugs. It is
classified under the drugs affecting brain cholinergic system, as
a central anticholinergic agent. Benzhexol (Artane) is essential
in the case of extrapyramidal syndrome induced by
phenothiazines and reserpines. It is used in the treatment of
Having meticulously discussed the carbamazepine,
haloperidol, chlorpromazine and a brief highlight on
multivitamins as well as benzhexol, the relevance of medication
in treating substance-induced disorders need not be over-
emphasized. However, extra care must be taken to avoid the
evils of such medicinal substances which would equally turn to
be acts of substance abuse. A high degree of professionalism is
needed in biological interventions or drug therapies just as in
The need to treat and rehabilitate persons with
substance-induced disorders is obvious and cogent because
there will be no meaningful social development if such social
cancer is left untreated. Hence, mental health care oughts to
keep improving day by day towards facilitating holistic well
being and positive human dignity. Ensuring a humane society
where drugs and mental health promotes economy and social
development should be the concern of professionals,
governments and other stakeholders. Don’t abuse substances,
join in preventing substances abuse, treat and rehabilitate
persons with substance-induced disorders” (Gandi J.C., 2008).
REFERENCES
(1) Alao, A.O. (2008). Hospital Admissions Record.
Department of Psychiatry, Specialist Hospital
(2) American Psychiatric Association (2001) . Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-
(3) Bennett & Whoolf (1991). Psychoparmacology for
subsyance Intoxication and substance Withdrawal.
In: Psychiatric/Mental Health Nursing (1999).
Printed in Philadelphia, F.A. Davis Company.
(4) Booth, B.M., Blow, F.C., Ludke, R.L. (1996). Utilization of
Acute Inpatient Services for Alcohol detoxification.
Journal of Mental Health Administration, 23:366-
(5) Gandi, J.C. (2004).Impact of Partnership – in – coping in
Mental Health Recovery. Experimental Study at
Federal Neuro-Psychiatric Hospital Kaduna,
(7) Lambo, T.A. (1996). Forward: In Drugs and the Nigerian
(8) Obot, I.S. (1996). Drugs and the Nigerian Society:
A comprehensive Annotated Bibliography, Nigeria,
(9) Psych Central (2006). A guide to Mental Health Clinic
(10) Schwartz, et al (1991). In: Guide to Drug Abuse
(11) Town send, M.C. (1999). Essentials of Psychiatric Mental
Health Nursing. Philadelphia, F.A. Davis Company.
(12) World Health Organization (2000). Guide to Drug Abuse
Les infirmières, les infirmières auxiliaires, le si n h a lo t h é ra p e u tes, les perfusionnistes, les puéri-c u l t r i ces, les gardes-bébés et les te c h n i c i e n n e sen circulation ex t ra - co r p o re l le œuvrent dans dif-f é rents types d’éta b l i ssements du réseau public,mais également dans des éta b l i ssements privé s . E l les fo u r n i ssent d
EU publishes Decision 2009/251/EC banning the use of dimethyl fumarate (DMF) Published today in the EU Official Journal is Commission Decision 2009/251/EC requiring Member States to ensure that products containing the biocide dimethylfumarate are not placed or made available on the market What is Dimethyl Fumarate? It is a substance which has been used as a fungic